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Abstract
Background: Follicle-stimulating hormone (FSH), a member of gonadotropin family, is critical for
follicular maturation and ovarian steroidogenesis. Serum FSH levels are known to fluctuate during
different phases of menstrual cycle in premenopausal women, and increase considerably after the
menopause as a result of ovarian function cessation. There is little existing evidence to guide
researchers in estimating the reliability of serum FSH measurements. The objective of this study
was to assess the reliability of FSH measurement using stored sera from an ongoing prospective
cohort – the NYU Women's Health Study.
Methods: Sixty healthy women (16 premenopausal, 44 postmenopausal), who donated at least
two blood samples at approximately 1-year intervals were studied. An immunoradiometric assay
using a sandwich monoclonal antibodies technique was used to measure FSH levels in serum.
Results: The reliability of a single log-transformed FSH measurement, as determined by the
intraclass correlation coefficient, was 0.70 for postmenopausal women (95% confidence interval
(CI), 0.55–0.82) and 0.09 for premenopausal women (95% CI, 0–0.54).
Conclusions: These results suggest that a single measurement is sufficient to characterize the
serum FSH level in postmenopausal women and could be a useful tool in epidemiological research.
For premenopausal women, however, the reliability coefficient was low, suggesting that a single
determination is insufficient to reliably estimate a woman's true average serum FSH level and
repeated measurements are desirable.
Background
Follicle-stimulating hormone (FSH) plays a key role in the
development and function of the reproductive system and
is widely used both in clinical and research settings. The
accurate and reliable measurement of FSH levels is essen-
tial for safe and successful treatment in developmental
and reproductive medicine [1], as well as for research
studies examining the association between FSH levels and
various disease outcomes.
FSH is a member of the gonadotropin family, which
includes also luteinizing hormone (LH) and human cho-
rionic gonadotropin (hCG). Gonadotropins are complex
heterodimeric glycoproteins which consist of two linked
protein components designated as the α- and β-subunits.
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The α-subunit is common to the three gonadotropins,
whereas the β-subunit confers specificity and biological
activity.
According to the "two cell, two gonadotropin" theory [2–
5], both FSH and LH are necessary for ovarian follicular
maturation and the syntheses of ovarian steroid hor-
mones. LH promotes the production of androgens (dehy-
droepiandrosterone, androstenedione, and testosterone)
from cholesterol and pregnenolone, by stimulating 17α-
hydroxylase activity in the thecal cells. The androgens
then diffuse to the granulosa cells where FSH stimulates
the expression of the cytochrome P450 aromatase, which
converts the androgens to estrogens [6,7].
The measurement of FSH in circulation is employed in the
diagnosis of disorders of reproduction and development,
whereas therapeutic preparations of FSH are widely used
for induction of ovulation in women and stimulation of
spermatogenesis in men [1]. The effects of gonadotropins
may not be limited to endocrine and reproductive func-
tions. Excessive gonadotropin stimulation of the ovarian
epithelium has been postulated to be one of the possible
mechanisms of ovarian carcinogenesis [8]. However,
studies that directly examined the association between
serum levels of gonadotropins and ovarian cancer risk
have not been consistent with this theory [9,10].
Before starting complex epidemiological studies examin-
ing the associations between FSH and various diseases, it
is important to assess the extent of the hormone's under-
lying fluctuations in circulation. FSH levels peak during
the menstruation and ovulatory phase and are lower dur-
ing the late follicular and luteal phases of the menstrual
cycle. After menopause, FSH levels gradually increase
through negative biofeedback as a result of ovarian func-
tion cessation. Given a substantial fluctuation of FSH lev-
els under normal physiological conditions, determination
of FSH in a single measurement may provide inadequate
estimates of the true average values over extended periods
of time.
The purpose of this preliminary study was to examine the
reliability of FSH measurements in premenopausal and
postmenopausal women using a subset of subjects with
repeated serum FSH measurements from the New York
University (NYU) Women's Health Study.
Methods
Study Population
Between March 1985 and June 1991, the NYU Women's
Health Study enrolled a cohort of 14,275 women aged
34–65 years, attending a breast screening clinic in New
York City [11,12]. The cohort was restricted to women
who in the preceding 6 months were neither pregnant nor
treated with hormones. At the time of enrollment and at
annual screening visits thereafter, subjects were asked to
complete questionnaires on medical, anthropometric,
reproductive, and dietary factors and to provide 30 mL of
non-fasting peripheral venous blood. Approximately half
of the participants gave blood at repeated visits, on aver-
age at 1-year intervals. After blood drawing, tubes were
kept covered at room temperature (20°C) for 15 minutes,
then at 4°C for 60 minutes to allow clot retraction, and
then centrifuged at 3500 rpm for 15 minutes. Supernatant
serum was partitioned into 1-mL aliquots and immedi-
ately stored at -80°C for future biochemical analyses.
The subjects for this study were selected from a subset of
the NYU Women's Health Study subjects participating in
a multi-center nested case-control study of body mass
index in relation to ovarian cancer [13] for whom serum
FSH levels were measured to verify their self-reported
menopausal status. Women were classified as premeno-
pausal if they reported at least one menstrual cycle during
the 6 months prior to enrollment. The number of days
prior to the next menses and the phase of the cycle were
calculated using calendars that the study subjects were
instructed to mark and return following their next menses
after enrollment. Women were classified as postmeno-
pausal if they reported absence of menstrual cycles in the
previous 6 months, a total bilateral oophorectomy, or a
hysterectomy without total oophorectomy if their age was
52 years or older. Postmenopausal status was confirmed
by serum FSH level greater than 12.5 mIU/mL, as previ-
ously described [13]. The subjects eligible for the current
study included women, who were free of cancer and who
had repeated FSH measurements within at least one-year
interval. A total of sixty healthy women: 16 premenopau-
sal (secretory phase), 44 postmenopausal, who have met
these eligibility criteria were selected to study the reliabil-
ity of FSH measurements in serum.
Laboratory Methods
Biochemical analyses of serum samples were performed at
the Laboratory of Hormones and Cancer Group, Interna-
tional Agency for Research on Cancer (IARC, Lyon,
France). Laboratory personnel were unaware of subjects'
case-control status and of the temporal sequence of the
samples. Repeated samples from the same subjects were
always analyzed in the same batch. Serum FSH was meas-
ured by an immunoradiometric assay (FSH IRMA, Diag-
nostic System Laboratories, TX, USA). The FSH IRMA is a
non-competitive assay in which the analyte is sandwiched
between two monoclonal antibodies. The first antibody is
coated on the walls of the tubes used in the analysis, while
the second antibody is radiolabeled for detection. The
unbound fraction is removed by a washing step. The
amount of radioactivity counted in the assay tubes is
directly proportional to the amount of analyte in theReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/49
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sample. A set of standards with known amount of FSH is
used to plot a standard curve from which the amount of
FSH in the samples can be calculated. Assay sensitivity: all
reported sample values were above the 0.11 mIU/mL
lower detection limit. Assay specificity: the FSH kit manu-
facturer (DSL, Texas, USA) reported no measurable cross-
reaction with other gonadotropins (LH and hCG). The
within-assay coefficients of variation provided by the
IARC laboratory were ranging from 3.2 to 4.6% depend-
ing on the serum FSH concentration.
Statistical Methods
The reliability was assessed by calculating the intraclass
correlation coefficients (reliability coefficients). Variance
components were estimated in an ANOVA analysis
assuming a one-way random effects model [14]. Compu-
tations were performed on the natural log-transformed
data in order to reduce the positive skewness of the raw
data. Exact 95% confidence intervals (CIs) were calculated
as described by Shrout and Fleiss [15]. A mixed effects
regression model was used to assess whether age, body
mass index (BMI = weight in kg/height in m2) or storage
time were predictive of FSH serum level. Spearman corre-
lation coefficients between FSH levels and these three
explanatory variables were also computed, separately for
each visit.
Results
Of the sixty women with repeated FSH measurements
included in the study, 16 were premenopausal and 44
were postmenopausal. Premenopausal women had a
mean age (± SD) at first blood donation of 43.7 (± 5.0)
years and a mean BMI of 25.5 kg/m2 (± 3.0 kg/m2). For
postmenopausal women, the mean age was 57.4 years (±
4.7 years) and the mean BMI was 25.9 kg/m2 (± 4.3 kg/
m2). Mean times in storage of the serum samples were
14.0 years (± 0.5 years) and 12.6 years (± 1.0 years) for the
first and subsequent visits, respectively.
Serum FSH values of the study subjects at enrollment and
during a repeat visit are presented in Table 1, according to
menopausal status. The FSH levels in the premenopausal
women at enrollment ranged from 0.4 to 8.9 mIU/mL
with a median of 2.6 mIU/mL. During the repeat visit
approximately one year later, their serum FSH levels were
higher, ranging from 1.2 to 19.1 mIU/mL with a median
of 4.5 mIU/mL. As expected, the baseline postmenopausal
FSH values were substantially higher, as compared to pre-
menopausal women, ranging from 13.5 to 71.1 mIU/mL
with a median of 43.1 mIU/mL.
Variance components and the resulting intraclass correla-
tion (reliability) coefficients computed on the natural log-
transformed data are shown in Table 2. Among premeno-
pausal women, the reliability coefficient for FSH was 0.09
(95% CI 0.0–0.54). The reliability coefficient for post-
menopausal women was 0.70 (95% CI 0.55–0.82). The
lower reliability in premenopausal women appears to be
related to greater within-subject variability before meno-
pause, since the within-subject variance component was
15-fold higher in the premenopausal women compared
to the postmenopausal group. In addition, the between-
subject variance component was greater in the postmeno-
pausal group than in the premenopausal women, suggest-
ing that this variance component may also contribute to
the observed differences in serum FSH reliability before
and after menopause.
Using a mixed effects regression model, neither age nor
storage duration were predictive of FSH level. There was a
marginally significant negative association between BMI
and FSH level (p  = 0.045). The Spearman correlation
coefficient between FSH level and BMI was -0.12 at the
first visit and -0.27 at the second visit.
Variability in the results of the laboratory assay (the
within-assay coefficient of variation) was only a small
Table 1: FSH levels and age at two visits in subset of healthy women, NYU Women's Health Study
Premenopausal N = 16 Postmenopausal N = 44
Visit 1 Visit 2 Visit 1 Visit 2
FSH values, mIU/mL
Median 2.6 4.5 43.1 44.1
Range 0.4–8.9 1.2–19.1 13.5–71.1 12.9–77.1
Mean 3.4 5.7 43.3 43.9
Standard deviation 2.6 4.2 13.6 14.4
Age at sampling, years
Median 42 43 58 59
Range 36–56 37–57 43–65 45–66
Mean 43.7 45.0 57.4 59.0
Standard deviation 5.0 4.8 4.7 4.8Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/49
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proportion of the total variability. The within-assay coef-
ficient of variation provided by the laboratory was ranging
from 3.2 to 4.6% depending on the serum FSH concentra-
tion (Table 2).
Discussion
The results demonstrate that the ability of a single meas-
urement to characterize a woman's long-term serum FSH
level depends on her menopausal status. For the postmen-
opausal women, the reliability of a single FSH measure-
ment was adequate (reliability coefficient = 0.70, 95% CI
0.55–0.82), which suggests that serum FSH levels are
fairly stable after menopause. For the premenopausal
women, the reliability of a single FSH measurement was
considerably worse (reliability coefficient = 0.09, 95% CI
0–0.54), which implies that FSH levels are more variable
in premenopausal women.
Variability due to the laboratory assay was reduced in the
current study by processing the samples from the same
subjects in the same batch. The low within-assay coeffi-
cients of variation (<5%) suggest that most of the within-
subject variability was the expression of real biological
variation and not due to laboratory measurement error. If
the samples were assayed at different times and if substan-
tial random batch-to-batch variation were present, the
reliability of the measurement would be somewhat lower
than the values presented here.
Variation in FSH levels during the menstrual cycle is
thought to be critical in the mechanism of FSH-dependent
selection of the dominant follicles [16] and could affect
the reliability estimates in premenopausal women. Lack
of storage time effect suggests that degradation of speci-
mens during long-term freezer-storage seems an unlikely
explanation for low reliability of FSH in premenopausal
women in the current study. In addition, the higher mean
FSH levels during the repeated visits and the mean age of
premenopausal women during the repeated visit (45
years) suggest that some of these women may have been
perimenopausal.
Although the ovarian function markedly decreases after
the menopause, gonadotropins may play a role in post-
menopausal women. Ovarian tissues from postmenopau-
sal women express gonadotropin receptors [17] and could
synthesize steroid hormones [18,19]. Longcope [20] has
shown that postmenopausal ovary is characterized by a
markedly decreased secretion of estrogens and certain
androgens, but the secretion of testosterone is preserved
to a large extent in most postmenopausal women. These
observations suggest that gonadotropin response and
endocrine function do not entirely cease after the meno-
pause and may play a role in certain hormone-dependent
conditions, such as polycystic ovaries [21].
The importance of assessing the reliability of exposure
measurement prior to planning the complex epidemio-
logical investigations is based on the fact that poor relia-
bility may reduce the effective sample size [22], result in a
loss of statistical power and a bias toward unity in relative
risk estimates [23]. The issue of reliability is even more
important for cohort studies utilizing prospectively col-
lected biological samples, where strategies to preserve the
valuable specimens for only reliable exposure measure-
ments should be given consideration.
In conclusion, the results of this study indicate that
whereas a single determination could be inadequate to
reliably estimate serum FSH in premenopausal women, a
single measurement may be sufficiently characteristic of
the average serum FSH levels in postmenopausal women.
These results have implications for the design of epidemi-
ological studies to evaluate the role of FSH in various hor-
mone-dependent conditions.
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FSH, follicle-stimulating hormone; LH, luteinizing hor-
mone; hCG, human chorionic gonadotropin; NYU, New
York University; IRMA, immunoradiometric assay; mIU/
mL, milli-international units per milliliter; ANOVA, anal-
ysis of variance; BMI, body mass index; CI, confidence
interval; SD, standard deviation.
Table 2: Between- and within-subject variance and reliability coefficients for serum FSH in subset of healthy women, NYU Women's 
Health Study
Premenopausal N = 16 Postmenopausal N = 44
Variance components
Between subjects 0.057 0.102
Within subjects 0.600 0.044
Reliability coefficient, ρ 0.09 0.70
95% confidence interval 0–0.54 0.55–0.82
Coefficient of variation, % (within-assay) 4.6 3.2Publish with BioMed Central    and   every 
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